Pharmacogenetics of asthma

Current Opinion in Pharmacology

Volumn 10, Issue 3, 2010, Pages 226-235

  Pascual, Rodolfo M ^a   Bleecker, Eugene R ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CYSTEINYL LEUKOTRIENE RECEPTOR 1; CYSTEINYL LEUKOTRIENE RECEPTOR 1 BLOCKING AGENT; CYSTEINYL LEUKOTRIENE RECEPTOR 2; FORMOTEROL; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; HEAT SHOCK PROTEIN 90; LEUKOTRIENE; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; LONG ACTING DRUG; MESSENGER RNA; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIASTHMATIC AGENT;

ASTHMA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HUMAN; NONHUMAN; PATHOGENESIS; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); GENETICS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; GLUCOCORTICOIDS; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; SEVERITY OF ILLNESS INDEX;

EID: 77954657711     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.05.013     Document Type: Review

References (48)

1. Moore W.C., Bleecker E.R., Curran-Everett D., Erzurum S.C., Ameredes B.T., Bacharier L., Calhoun W.J., Castro M., Chung K.F., Clark M.P., et al. Characterization of the severe asthma phenotype by the National Heart. Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007, 119:405-413.
2. Moore W.C., Meyers D.A., Wenzel S.E., Teague W.G., Li H., Li X., D'Agostino R., Castro M., Curran-Everett D., Fitzpatrick A.M., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010, 181:315-323.
3. Hawkins G.A., Weiss S.T., Bleecker E.R. Clinical consequences of ADRbeta2 polymorphisms. Pharmacogenomics 2008, 9:349-358.
4. Ortega V.E., Hawkins G.A., Peters S.P., Bleecker E.R. Pharmacogenetics of the beta 2-adrenergic receptor gene. Immunol Allergy Clin North Am 2007, 27:665-684.
5. Bleecker E.R., Yancey S.W., Baitinger L.A., Edwards L.D., Klotsman M., Anderson W.H., Dorinsky P.M. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006, 118:809-816.
6. Bleecker E.R., Postma D.S., Lawrance R.M., Meyers D.A., Ambrose H.J., Goldman M. Effect of ADRB2 polymorphisms on response to long acting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007, 370:2118-2125.
7. Bleecker E.R., Nelson H.S., Kraft M., Corren J., Meyers D.A., Yancey S.W., Anderson W.H., Emmett A.H., Ortega H.G. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010, 181:676-687.
8. Israel E., Drazen J.M., Liggett S.B., Boushey H.A., Cherniack R.M., Chinchilli V.M., Cooper D.M., Fahy J.V., Fish J.E., Ford J.G., et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000, 162:75-80.
9. Israel E., Chinchilli V.M., Ford J.G., Boushey H.A., Cherniack R., Craig T.J., Deykin A., Fagan J.K., Fahy J.V., Fish J., et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004, 364:1505-1512.
10. Wechsler M.E., Lehman E., Lazarus S.C., Lemanske R.F., Boushey H.A., Deykin A., Fahy J.V., Sorkness C.A., Chinchilli V.M., Craig T.J., et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006, 173:519-526.
11. Wechsler M.E., Kunselman S.J., Chinchilli V.M., Bleecker E., Boushey H.A., Calhoun W.J., Ameredes B.T., Castro M., Craig T.J., Denlinger L., et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009, 374:1754-1764.
12. Reihsaus E., Innis M., MacIntyre N., Liggett S.B. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993, 8:334-339.
13. Green S.A., Turki J., Innis M., Liggett S.B. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994, 33:9414-9419.
14. Green S.A., Turki J., Bejarano P., Hall I.P., Liggett S.B. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995, 13:25-33.
15. McGraw D.W., Forbes S.L., Kramer L.A., Liggett S.B. Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 1998, 102:1927-1932.
16. Drysdale C.M., McGraw D.W., Stack C.B., Stephens J.C., Judson R.S., Nandabalan K., Arnold K., Ruano G., Liggett S.B. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000, 97:10483-10488.
17. Drazen J.M., Israel E., Boushey H.A., Chinchilli V.M., Fahy J.V., Fish J.E., Lazarus S.C., Lemanske R.F., Martin R.J., Peters S.P., et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996, 335:841-847.
18. Taylor D.R., Drazen J.M., Herbison G.P., Yandava C.N., Hancox R.J., Town G.I. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000, 55:762-767.
19. Crane J., Pearce N., Flatt A., Burgess C., Jackson R., Kwong T., Ball M., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989, 1:917-922.
20. Sears M.R., Taylor D.R. Regular beta-agonist therapy-the quality of the evidence. Eur Respir J 1992, 5:896-897.
21. Stolley P.D. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972, 105:883-890.
22. Castle W., Fuller R., Hall J., Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993, 306:1034-1037.
23. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006, 129:15-26.
24. Kuna P., Peters M.J., Manjra A.I., Jorup C., Naya I.P., Martinez-Jimenez N.E., Buhl R. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007, 61:725-736.
25. Hawkins G.A., Tantisira K., Meyers D.A., Ampleford E.J., Moore W.C., Klanderman B., Liggett S.B., Peters S.P., Weiss S.T., Bleecker E.R. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006, 174:1101-1109.
26. Ng S.B., Turner E.H., Robertson P.D., Flygare S.D., Bigham A.W., Lee C., Shaffer T., Wong M., Bhattacharjee A., Eichler E.E., et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009, 461:272-276.
27. Himes B.E., Hunninghake G.M., Baurley J.W., Rafaels N.M., Sleiman P., Strachan D.P., Wilk J.B., Willis-Owen S.A., Klanderman B., Lasky-Su J., et al. Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet 2009, 84:581-593.
28. Tantisira K.G., Drazen J.M. Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol 2009, 124:422-427.
29. Drazen J.M., Yandava C.N., Dube L., Szczerback N., Hippensteel R., Pillari A., Israel E., Schork N., Silverman E.S., Katz D.A., Drajesk J. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999, 22:168-170.
30. Lima J.J., Zhang S., Grant A., Shao L., Tantisira K.G., Allayee H., Wang J., Sylvester J., Holbrook J., Wise R., et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006, 173:379-385.
31. Pillai S.G., Cousens D.J., Barnes A.A., Buckley P.T., Chiano M.N., Hosking L.K., Cameron L.A., Fling M.E., Foley J.J., Green A., et al. A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. Pharmacogenetics 2004, 14:627-633.
32. Sanak M., Pierzchalska M., Bazan-Socha S., Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000, 23:290-296.
33. Malmstrom K., Rodriguez-Gomez G., Guerra J., Villaran C., Pineiro A., Wei L.X., Seidenberg B.C., Reiss T.F. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Ann Intern Med 1999, 130:487-495. Montelukast/Beclomethasone Study Group.
34. Szefler S.J., Phillips B.R., Martinez F.D., Chinchilli V.M., Lemanske R.F., Strunk R.C., Zeiger R.S., Larsen G., Spahn J.D., Bacharier L.B., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005, 115:233-242.
35. Adcock I.M., Barnes P.J. Molecular mechanisms of corticosteroid resistance. Chest 2008, 134:394-401.
36. Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet 2009, 373:1905-1917.
37. Tantisira K.G., Lake S., Silverman E.S., Palmer L.J., Lazarus R., Silverman E.K., Liggett S.B., Gelfand E.W., Rosenwasser L.J., Richter B., et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004, 13:1353-1359.
38. Schoneveld O.J., Gaemers I.C., Lamers W.H. Mechanisms of glucocorticoid signalling. Biochim Biophys Acta 2004, 1680:114-128.
39. Pratt W.B., Galigniana M.D., Harrell J.M., DeFranco D.B. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal 2004, 16:857-872.
40. Tantisira K.G., Hwang E.S., Raby B.A., Silverman E.S., Lake S.L., Richter B.G., Peng S.L., Drazen J.M., Glimcher L.H., Weiss S.T. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A 2004, 101:18099-18104.
41. Hawkins G.A., Amelung P.J., Smith R.S., Jongepier H., Howard T.D., Koppelman G.H., Meyers D.A., Bleecker E.R., Postma D.S. Identification of polymorphisms in the human glucocorticoid receptor gene (NR3C1) in a multi-racial asthma case and control screening panel. DNA Seq 2004, 15:167-173.
42. Huizenga N.A., Koper J.W., de L.P., Pols H.A., Stolk R.P., Burger H., Grobbee D.E., Brinkmann A.O., de Jong F.H., Lamberts S.W. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998, 83:144-151.
43. Hawkins G.A., Lazarus R., Smith R.S., Tantisira K.G., Meyers D.A., Peters S.P., Weiss S.T., Bleecker E.R. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J Allergy Clin Immunol 2009, 123:1376-1383.
44. Adcock I.M., Tsaprouni L., Bhavsar P., Ito K. Epigenetic regulation of airway inflammation. Curr Opin Immunol 2007, 19:694-700.
45. Gilliland F.D., Li Y.F., Peters J.M. Effects of maternal smoking during pregnancy and environmental tobacco smoke on asthma and wheezing in children. Am J Respir Crit Care Med 2001, 163:429-436.
46. Camargo C.A., Rifas-Shiman S.L., Litonjua A.A., Rich-Edwards J.W., Weiss S.T., Gold D.R., Kleinman K., Gillman M.W. Maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in children at 3 y of age. Am J Clin Nutr 2007, 85:788-795.
47. Giacomini K.M., Brett C.M., Altman R.B., Benowitz N.L., Dolan M.E., Flockhart D.A., Johnson J.A., Hayes D.F., Klein T., Krauss R.M., et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007, 81:328-345.
48. Himes B.E., Wu A.C., Duan Q.L., Klanderman B., Litonjua A.A., Tantisira K., Ramoni M.F., Weiss S.T. Predicting response to short-acting bronchodilator medication using Bayesian networks. Pharmacogenomics 2009, 10:1393-1412.